{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T19:20:09Z","timestamp":1776108009073,"version":"3.50.1"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jpba.2026.117459","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T17:24:24Z","timestamp":1773249864000},"page":"117459","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Isolation and identification of the designer benzodiazepine cyclopropylflualprazolam in pressed candies marketed for sleep improvement"],"prefix":"10.1016","volume":"275","author":[{"given":"Xiaopu","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peizhi","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4504-4248","authenticated-orcid":false,"given":"Xiaowei","family":"Ge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinhua","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2026.117459_bib1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3390\/toxics9020025","article-title":"Benzodiazepines: their use either as essential medicines or as toxics substances","volume":"9","author":"Sanabria","year":"2019","journal-title":"Toxics"},{"key":"10.1016\/j.jpba.2026.117459_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2020.113151","article-title":"Large scale consumption monitoring of benzodiazepines and z-drugs by hair analysis","volume":"183","author":"Madry","year":"2020","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"1","key":"10.1016\/j.jpba.2026.117459_bib3","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/dta.2203","article-title":"Flubromazolam-basic pharmacokinetic evaluation of a highly potent designer benzodiazepine","volume":"10","author":"Huppertz","year":"2019","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.jpba.2026.117459_bib4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.neuro.2019.02.015","article-title":"An expanding world of new psychoactive substances-designer benzodiazepines","volume":"73","author":"Zawilska","year":"2019","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.jpba.2026.117459_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2020.113779","article-title":"An analytical strategy for designer benzodiazepines and Z-hypnotics determination in plasma samples using ultra-high performance liquid chromatography\/tandem mass spectrometry after microextraction by packed sorbent","volume":"194","author":"Ares-Fuentes","year":"2021","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117459_bib6","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jpsychires.2020.05.020","article-title":"Benzodiazepine misuse among adults receiving psychiatric treatment","volume":"128","author":"Mchugh","year":"2020","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jpba.2026.117459_bib7","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/FTD.0000000000001071","article-title":"Designer benzodiazepines: effects, toxicity, and interactions","volume":"45","author":"Balkhi","year":"2023","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jpba.2026.117459_bib8","unstructured":"UNODC LSS, The challenge of new psychoactive substances-a technical update 2024. \u3008https:\/\/www.unodc.org\/documents\/scientific\/The_Challenge_of_NPS_A_technical_update_2024.pdf\u3009, 2024 (accessed 13 Nov 2025)."},{"key":"10.1016\/j.jpba.2026.117459_bib9","doi-asserted-by":"crossref","first-page":"560","DOI":"10.3390\/ph14060560","article-title":"Designer benzodiazepines: a review of toxicology and public health risks","volume":"14","author":"Brunetti","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.jpba.2026.117459_bib10","unstructured":"UNODC, Current NPS threats volume IV. \u3008https:\/\/www.unodc.org\/documents\/scientific\/NPS_threats-IV.pdf\u3009, 2021 (accessed 13 Nov 2025)."},{"key":"10.1016\/j.jpba.2026.117459_bib11","unstructured":"UNODC, Current NPS threats volume V. \u3008https:\/\/www.unodc.org\/documents\/scientific\/Current_NPS_Threats_V.pdf\u3009, 2022 (accessed 13 Nov 2025)."},{"key":"10.1016\/j.jpba.2026.117459_bib12","unstructured":"UNODC, Current NPS threats volume VI. \u3008https:\/\/www.unodc.org\/res\/scientists\/ewa\/Current_NPS_Threats_VI.pdf\u3009, 2023 (accessed 13 Nov 2025)."},{"key":"10.1016\/j.jpba.2026.117459_bib13","unstructured":"UNODC, Current NPS threats volume VII. \u3008https:\/\/www.unodc.org\/documents\/scientific\/Current_NPS_threats_VII.pdf\u3009, 2024 (accessed 13 Nov 2025)."},{"key":"10.1016\/j.jpba.2026.117459_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2023.116459","article-title":"Designer benzodiazepine rat pharmacokinetics: a comparison of alprazolam, flualprazolam and flubromazolam","volume":"465","author":"Canfield","year":"2023","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.jpba.2026.117459_bib15","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s11419-019-00501-1","article-title":"Identification of the designer benzodiazepine 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine (flualprazolam) in an anesthesia robbery case","volume":"38","author":"Qian","year":"2020","journal-title":"Forensic Toxicol."},{"key":"10.1016\/j.jpba.2026.117459_bib16","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.1093\/jat\/bkac023","article-title":"Reports of adverse events associated with use of novel psychoactive substances, 2017\u20132020: a review","volume":"46","author":"Mohr","year":"2022","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.jpba.2026.117459_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115936","article-title":"Analysis on dynamic changes of etizolam and its metabolites and exploration of its development prospect using UPLC-Q-exactive-MS","volume":"240","author":"Jie","year":"2024","journal-title":"J. Pharm. Biomed. Anal."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708526001275?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708526001275?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T17:49:11Z","timestamp":1776102551000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708526001275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":17,"alternative-id":["S0731708526001275"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2026.117459","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Isolation and identification of the designer benzodiazepine cyclopropylflualprazolam in pressed candies marketed for sleep improvement","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2026.117459","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117459"}}